≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Internuclear ophthalmoplegia

DOID Endpoint Browser PheWeb

H7_INTERNUCOPHTHALMOPLEGIA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — H51.2
  • Cause of death: ICD-10 — H51.2

2 out of 7 registries used, show all original rules.

151

4. Check minimum number of events

None

151

5. Include endpoints

None

151

6. Filter based on genotype QC (FinnGen only)

131

Control definitions (FinnGen only)

Control exclude
H7_OCUMUSCLE

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
H51
Name in latin
Ophthalmoplegia internuclearis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 744 360 381
Only index persons 703 351 352
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 53.28 49.63 56.83
Only index persons 52.66 49.17 56.15

-FinnGen-

Key figures

All Female Male
Number of individuals 131 73 58
Unadjusted period prevalence (%) 0.03 0.03 0.03
Median age at first event (years) 51.84 45.15 60.26

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
139
Matched controls
1390
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
200.8
139
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
14.3
46.3
51
54
G35
ICD-10 Finland
Multiple sclerosis
76.8
39.1
43
8
H53.2
ICD-10 Finland
Diplopia
38.1
31.0
39
14
109
Kela drug reimbursment
Multiple sclerosis
51.3
27.2
32
8
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
53.9
25.8
30
7
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
45.2
21.7
26
7
XCK00
NOMESCO Finland
Perimetry
9.6
19.4
25
31
N86
ICPC
Multiple sclerosis
109.2
18.0
19
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
72.7
17.2
19
*
L03AB07
ATC
interferon beta-1a; parenteral
54.5
16.5
19
*
L03AX13
ATC
glatiramer acetate; parenteral
54.5
16.5
19
*
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
5.9
16.5
35
75
TAB00
NOMESCO Finland
Lumbar puncture
13.7
16.2
28
25
AA1AD
NOMESCO Finland
CT of head and brain
4.1
15.1
65
244
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
+∞
12.7
12
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.8
12.6
33
84
H46
ICD-10 Finland
Optic neuritis
25.7
10.5
14
6
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.6
10.5
28
72
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.7
9.8
39
134
N04BB01
ATC
amantadine; oral
32.6
9.6
12
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.7
9.3
36
121
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
18.6
8.2
12
7
N03AX16
ATC
[U] pregabalin
3.0
7.9
45
190
164
Kela drug reimbursment
Fingolimod
47.7
7.8
9
*
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
7.4
7
*
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
+∞
7.4
7
*
2AB04, ,
NOMESCO Finland
+∞
7.4
7
*
R42
ICD-10 Finland
Dizziness and giddiness
2.8
7.1
45
201
M03BX01
ATC
baclofen; systemic
11.8
6.9
12
11
H53.1
ICD-10 Finland
Subjective visual disturbances
4.2
6.9
20
54
353
Kela drug reimbursment
Cladribine and fingolimod
42.2
6.8
8
*
N07AA02
ATC
pyridostigmine; systemic
42.2
6.8
8
*
B01AC30
ATC
platelet aggregation inhibitors excl. heparin - combinations
4.6
6.8
17
41
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
73.1
6.5
7
*
L04AA27
ATC
[U] fingolimod
73.1
6.5
7
*
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
6.3
6
*
G46.3*I67.9
ICD-10 Finland
Brain stem stroke syndrome (I60-I67+)
+∞
6.3
6
*
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
+∞
6.3
6
*
108
Kela drug reimbursment
Myasthenia gravis
+∞
6.3
6
*

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
30
21
17.86
19.20
1.3
1.3
666.10
485.52
mg/l
0.34
30
21
22
16
16.07
13.80
1.4
1.4
—
—
—
0
0
17
11
17.39
11.16
1.4
1.2
—
—
—
0
0
18
15
13.58
10.70
1.2
1.3
—
—
—
0
0
14
7
22.01
10.03
1.6
1.1
—
—
—
0
0
73
409
2.65
7.40
10.5
5.7
—
—
—
0
0
9
5
19.08
6.35
3.9
2.6
2.22
4.60
%
—
9
5
84
535
2.44
6.09
5.2
3.4
6.40
6.22
ph
0.66
49
310
95
644
2.50
5.94
10.9
6.3
1.76
1.98
e9/l
0.81
85
577
94
635
2.48
5.91
11.1
6.3
0.05
0.04
e9/l
0.72
85
545
96
656
2.50
5.86
11.0
6.6
0.20
0.19
e9/l
0.17
86
584
40
186
2.62
5.69
1.9
1.6
922.72
1246.43
nmol/l
1.70
29
144
93
633
2.42
5.63
11.1
6.3
0.55
0.57
e9/l
0.26
84
546
105
776
2.44
4.95
7.8
4.3
—
65.40
—
0
10
57
340
2.15
4.46
4.8
2.6
—
—
—
0
0
95
706
2.09
3.95
13.1
10.5
4.31
4.12
e9/l
0.27
85
620
14
45
3.35
3.77
4.2
2.0
—
—
—
0
0
90
670
1.97
3.55
5.7
3.6
0.00
0.00
estimate
-0.00
17
135
12
32
4.00
3.48
1.8
2.8
—
—
—
0
0
89
664
1.95
3.44
5.6
3.6
0.00
0.00
estimate
-0.00
16
134
11
29
4.03
3.26
1.9
1.2
—
—
—
0
0
23
106
2.40
3.25
1.6
1.7
—
—
—
0
0
7
11
6.63
3.22
2.1
1.6
-1.56
-0.63
mmol/l
—
7
11
14
50
3.00
3.19
6.5
3.1
—
—
—
0
0
38
218
2.02
3.16
1.7
1.7
—
—
—
0
0
6
8
7.77
3.08
4.8
2.8
16.67
11.50
%
—
6
8
5
5
10.30
3.00
5.2
2.4
28.00
32.40
%
—
5
5
92
713
1.86
2.96
7.1
4.9
6.74
6.56
mmol/l
0.31
87
675
88
677
1.82
2.85
5.6
3.6
0.00
0.00
estimate
-0.00
16
127
73
536
1.76
2.73
22.2
12.1
1.21
1.21
inr
0.03
67
434
28
153
2.04
2.63
3.8
3.3
4.06
4.36
e9/l
0.19
23
136
19
89
2.31
2.59
8.5
5.3
7.39
7.35
ph
0.71
13
66
42
270
1.80
2.43
2.2
2.0
—
—
—
0
0
70
520
1.70
2.43
9.9
6.6
1.22
1.21
mmol/l
0.63
65
485
11
39
2.97
2.40
1.8
2.1
23.12
23.49
mmol/l
0.10
11
39
15
67
2.39
2.27
1.1
3.2
—
—
—
0
0
74
573
1.62
2.09
12.7
7.4
1.22
1.20
mmol/l
1.01
64
496
47
326
1.67
2.04
5.4
4.6
—
—
—
0
0
50
355
1.64
1.98
6.1
2.6
0.25
0.44
e6/l
0.81
39
248
26
153
1.86
1.97
1.7
1.7
—
—
—
0
0
13
59
2.33
1.91
2.7
1.8
687.80
6552.06
u/l
—
5
18
63
477
1.59
1.90
7.2
3.6
93.68
58.22
e6/l
0.28
43
321
10
40
2.61
1.70
1.2
1.3
—
—
—
0
0
61
469
1.54
1.67
5.3
3.4
20.44
43.54
ng/l
1.35
51
322
47
341
1.57
1.66
6.2
2.6
—
—
estimate
—
0
0
43
306
1.59
1.65
3.3
2.0
3.39
2.72
mg/l
0.63
37
274
6
20
3.09
1.60
4.3
1.8
3.12
4.92
e9/l
—
6
20
66
522
1.50
1.56
2.5
2.0
92.33
96.91
pmol/l
0.36
42
260
40
284
1.57
1.54
5.7
3.7
1.02
1.02
kg/l
0.21
26
181
24
150
1.73
1.50
1.5
1.9
—
—
—
0
0
49
367
1.52
1.48
6.0
3.6
0.00
0.00
estimate
-0.00
15
126
106
932
1.58
1.47
9.1
8.4
88.95
76.13
u/l
0.74
96
877
18
104
1.84
1.45
10.7
7.4
14.17
9.43
mmol/l
0.57
18
99
7
29
2.49
1.41
1.0
1.5
—
—
—
0
0
18
106
1.80
1.37
2.2
1.9
—
0.00
estimate
—
0
23
49
373
1.48
1.36
6.0
4.1
7.40
7.40
ph
0.13
39
255
29
197
1.60
1.34
6.0
2.7
9.25
1.72
e6/l
0.83
13
93
22
140
1.68
1.30
2.5
1.5
—
—
—
0
0
52
404
1.46
1.29
4.4
3.3
7.10
8.24
mmol/l
1.00
38
333
53
414
1.45
1.28
6.0
2.8
18.30
64.59
e6/l
1.75
41
304
24
157
1.64
1.28
1.3
1.2
—
—
—
0
0
78
655
1.43
1.28
7.6
7.0
10.05
11.37
umol/l
0.85
73
622
47
360
1.46
1.25
2.1
1.6
21.21
20.96
nmol/l
0.03
39
303
8
153
0.49
1.23
1.1
1.4
—
—
—
0
0
6
26
2.36
1.20
1.7
1.7
—
—
—
0
0
51
403
1.42
1.14
4.3
3.7
—
—
—
0
0
7
30
2.40
1.14
4.1
1.7
60.80
61.10
%
—
7
30
15
237
0.59
1.12
2.7
3.2
0.76
0.74
ug/l
—
10
154
40
509
0.70
1.09
3.2
3.1
—
—
—
0
0
47
370
1.41
1.06
4.7
3.6
97.32
62.08
mg/l
0.36
33
253
33
247
1.44
0.98
1.9
1.7
332.54
460.91
pmol/l
2.15
26
213
11
62
1.84
0.97
2.5
2.1
—
0.00
estimate
—
0
17
67
567
1.35
0.96
15.0
11.2
0.00
0.00
e9/l
0.42
55
462
61
509
1.35
0.96
5.9
3.5
0.07
0.00
estimate
0.48
15
113
13
78
1.74
0.95
4.1
9.0
25.21
24.79
mmol/l
0.23
13
78
113
1202
0.68
0.92
6.7
5.6
2.46
2.71
mmol/l
2.36
102
1122
101
916
1.38
0.89
5.3
4.4
14.75
14.65
pmol/l
0.15
95
844
13
80
1.69
0.88
1.0
1.2
—
—
—
0
0
6
31
1.98
0.85
3.3
1.3
—
—
—
0
0
126
1192
1.61
0.85
23.4
15.2
22.35
22.22
mg/l
0.02
101
989
8
46
1.78
0.84
2.8
1.3
—
—
—
0
0
16
106
1.58
0.83
1.4
1.1
—
—
—
0
0
47
385
1.33
0.81
5.8
4.1
15.10
9.55
mg/mmol
0.31
29
249
0
24
0.00
0.80
0.0
1.0
—
2.08
—
0
12
5
24
2.12
0.75
1.2
2.2
94.90
89.19
%
—
5
24
34
269
1.35
0.74
2.0
1.3
2.09
2.28
g/l
0.36
26
166
15
101
1.54
0.74
8.9
9.8
—
—
—
0
0
16
110
1.51
0.72
6.6
3.3
—
—
—
0
0
5
27
1.88
0.69
1.4
3.0
5.06
4.99
kpa
—
5
27
112
1181
0.73
0.67
6.0
5.0
4.35
4.63
mmol/l
2.18
101
1105
15
105
1.48
0.63
8.7
8.3
1.46
1.42
mmol/l
0.07
15
105
0
21
0.00
0.60
0.0
1.2
—
—
—
0
0
0
23
0.00
0.59
0.0
1.0
—
1.04
—
0
10
6
35
1.75
0.58
1.0
1.2
7.64
4.62
u/l
—
6
27
6
37
1.65
0.56
1.3
1.1
—
—
—
0
0
10
68
1.51
0.48
2.4
2.5
0.51
0.61
%
—
10
68
113
1178
0.78
0.46
6.0
4.8
1.40
1.46
mmol/l
0.99
102
1097
10
69
1.48
0.45
2.4
2.5
1.16
1.35
%
—
10
69
5
31
1.64
0.43
1.6
3.6
7.41
7.43
ph
—
5
31
10
70
1.46
0.43
1.1
1.2
—
—
—
0
0
5
32
1.58
0.42
1.2
2.1
9.78
7.91
kpa
—
5
32
127
1230
1.38
0.42
23.5
13.6
—
—
—
0
0
35
300
1.22
0.42
6.7
5.5
—
—
—
0
0
5
33
1.53
0.42
4.4
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.9
—
—
—
0
0
0
16
0.00
0.41
0.0
3.5
—
—
—
0
0
8
60
1.35
0.41
2.8
1.3
—
—
—
0
0
5
34
1.49
0.41
1.4
1.2
—
—
—
0
0
5
76
0.65
0.37
1.2
1.2
6.40
23.47
iu/l
—
5
64
5
79
0.62
0.36
1.2
1.1
—
—
—
0
0
6
43
1.41
0.35
1.0
1.3
—
—
—
0
0
6
43
1.41
0.35
1.0
1.9
60.50
42.16
nmol/l
—
6
43
42
373
1.18
0.35
1.5
1.5
—
—
—
0
0
18
219
0.80
0.34
1.3
1.3
1.03
4.79
u/ml
—
6
87
13
101
1.32
0.33
2.2
4.4
0.17
0.97
%
—
6
37
12
92
1.33
0.33
2.6
4.4
0.40
0.62
%
—
5
30
29
250
1.20
0.33
5.9
3.7
217.38
248.29
ng/l
0.06
24
183
10
130
0.75
0.31
1.6
1.9
—
—
—
0
0
8
108
0.73
0.30
1.4
1.3
—
—
—
0
0
46
417
1.15
0.29
4.3
2.3
—
—
—
0
0
107
1108
0.85
0.29
8.2
6.2
39.94
39.23
mmol/mol
0.29
100
1049
20
170
1.21
0.26
1.2
1.3
816.00
385.95
titre
—
5
37
0
11
0.00
0.21
0.0
19.2
—
1305.27
—
0
11
0
11
0.00
0.21
0.0
1.1
—
0.08
—
0
6
0
11
0.00
0.21
0.0
12.7
—
806.64
—
0
11
0
10
0.00
0.21
0.0
1.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.9
—
71.33
—
0
12
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
15
127
1.20
0.20
13.5
8.7
7.42
7.41
ph
—
7
75
62
585
1.11
0.20
4.6
2.8
—
—
estimate
—
0
0
0
14
0.00
0.20
0.0
2.9
—
31.71
—
0
14
42
388
1.12
0.20
4.9
5.5
5.63
2.83
ug/l
0.42
36
348
63
596
1.10
0.19
4.1
3.1
153.38
119.87
ug/l
0.24
58
571
6
52
1.16
0.19
5.8
4.6
37.00
36.92
°c
—
6
52
7
59
1.20
0.18
3.0
1.3
—
—
—
0
0
7
61
1.16
0.18
3.0
1.3
—
—
—
0
0
7
61
1.16
0.18
3.0
1.3
—
—
—
0
0
18
158
1.16
0.17
1.7
1.5
—
—
—
0
0
17
149
1.16
0.16
1.4
2.0
50.82
110.45
ug/g
1.10
11
122
6
77
0.77
0.16
1.3
2.0
—
—
—
0
0
41
384
1.10
0.15
5.1
3.1
0.00
0.01
estimate
0.50
14
110
34
316
1.10
0.14
2.6
2.9
314.24
336.69
umol/l
0.45
25
279
39
366
1.09
0.13
9.1
6.6
—
—
—
0
0
27
292
0.91
0.13
1.7
1.7
0.59
1.53
mg/l
2.50
21
231
15
167
0.89
0.11
1.2
1.3
—
—
—
0
0
10
86
1.18
0.11
3.8
4.3
1.22
1.22
mmol/l
—
10
75
14
125
1.13
0.10
14.3
8.8
1.56
0.57
mmol/l
0.65
14
106
15
135
1.12
0.10
1.5
1.3
—
—
—
0
0
17
186
0.90
0.10
2.4
1.9
—
—
—
0
0
31
292
1.08
0.09
1.6
1.3
0.66
1.32
u/ml
—
7
80
5
48
1.04
0.09
2.8
4.1
69.00
259.35
u/ml
—
5
43
6
56
1.07
0.09
6.7
3.4
1.02
1.02
ratio
—
6
51
7
63
1.12
0.08
11.6
4.6
—
—
—
0
0
8
76
1.06
0.07
1.9
3.3
25.23
24.04
mmol/l
—
8
76
12
132
0.90
0.07
1.5
1.4
—
—
—
0
0
9
101
0.88
0.06
2.8
2.7
6.65
0.17
e6/l
—
9
94
52
533
0.96
0.05
1.8
1.9
1.67
1.34
mmol/l
1.36
44
452
102
1008
1.04
0.04
27.4
18.8
13.68
13.58
%
0.30
102
999
16
170
0.93
0.04
10.1
7.2
104.69
104.21
mmol/l
0.16
16
170
49
498
0.98
0.01
1.7
2.1
—
—
—
0
0
16
164
0.97
0.00
1.4
1.4
—
—
—
0
0
112
1118
1.01
0.00
5.1
4.1
1.41
1.27
mmol/l
1.08
100
1040
113
1132
0.99
0.00
5.8
4.9
6.02
5.90
mmol/l
0.40
97
1046
0
9
0.00
0.00
0.0
10.1
—
0.61
—
0
9
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
6
61
0.98
-0.00
3.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.4
—
51.00
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
13.60
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
14.62
—
0
5
0
6
0.00
-0.00
0.0
2.3
—
16.52
—
0
6
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
27.80
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
83.25
—
0
8
0
8
0.00
-0.00
0.0
1.9
—
6.85
—
0
8
0
5
0.00
-0.00
0.0
1.0
—
0.60
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
11
110
1.00
-0.00
1.5
2.3
9.74
13.89
nmol/l
0.83
11
103

Mortality – FinRegistry

↥

Association

Association between endpoint H7_INTERNUCOPHTHALMOPLEGIA and mortality.

Females

No data

Males

Parameter HR [95% CI] p-value
H7_INTERNUCOPHTHALMOPLEGIA 1.405 [1.03, 1.92] 0.033
Birth year 0.987 [0.98, 1.0] 0.007

During the follow-up period (1.1.1998 — 31.12.2019), 84 out of 347 males with H7_INTERNUCOPHTHALMOPLEGIA died.

Mortality risk

Mortality risk for people of age

years, who have H7_INTERNUCOPHTHALMOPLEGIA.

N-year risk Females Males
1 No data 0.289%
5 No data 1.514%
10 No data 3.942%
15 No data 7.271%
20 No data 12.622%

Relationships between endpoints

↥

Index endpoint: H7_INTERNUCOPHTHALMOPLEGIA – Internuclear ophthalmoplegia

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data